+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Active Pharmaceutical Ingredient Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4701683
  • Report
  • Region: Global
  • Acute Market Reports
1 of 3

FEATURED COMPANIES

  • AbbVie Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Lonza Group
  • MORE
Active Pharmaceutical Ingredient Market Growth, Future Prospects, and Competitive Analysis, 2018 - 2026 the active pharmaceutical ingredient market was valued at US$ 152.6 Bn in 2017 and expected to reach US$ 273.5 Mn by 2026 at a CAGR of 6.7 % during the forecast period from 2018 to 2026.

Market Insights
The global active pharmaceutical ingredient (API) market shows fruitful growth during the forecast period from 2018 to 2026. The API is the active part of any drug that delivers its reaction. Many times a drug may contain few APIs and the reaction to a specific medication will rely upon the prescription of the dosage pattern, which changes from individual to individual. For instance, combination therapeutic treatments have various dynamic active ingredients to treat different side effects. TEVA Pharmaceuticals is one of the leading manufacturers of APIs in the global market having a vast portfolio of API products of around 300 APIs. Dr. Reddy's is also a leading API maker using more than 60 APIs currently.

North America to contribute maximum revenue share in the global active pharmaceutical ingredient market attributed to rising chronic diseases, higher adoption of prescribed drugs, demand for specialty drugs & biologics, increasing awareness, and rise in R&D for new drug formulations and development. In the current scenario, manufacturers present in the U.S. and Europe region are expanding their manufacturing capacity for APIs in the developing nations such as in India and China to cut expenses. This has made noteworthy changes in how these drugs are regulated, with more specific guidelines and regulations. For example, presently AstraZeneca Plc produce only 15% of their APIs in the U.S.

However, there are plans to end that small ratio and outsource all the manufacturing assembly in the Asia Pacific and Latin America market. Increase in healthcare spending is a global phenomenon, and this directly benefited the generics API market in recent years in the developing nations due to high demand and ease of access. However, the cost of enhancing process outline, higher cost of specialty API drugs, and stringent approvals regulations may act as a restraining factor to the overall development of the API market. Improvement of new inventive API's and inorganic development through mergers and partnerships with smaller organizations additionally support the API market in the developing nations. Adoption of branded generic drugs & medications is growing exponentially in developing economies, for example, in India and China. In addition, rising utilization of specialty drugs expected to increase the pharmaceutical spending around the world.

Increase in demand for advanced therapeutics for treatment of alarming diseases, rising prevalence for chronic diseases and lifestyle diseases globally along with increasing purchasing power, beneficiary schemes for reimbursement are various factors fueling the demand for active pharmaceutical ingredient market in near future.

Key Market Movements:
  • Globally, the active pharmaceutical ingredient market expected to exhibit a profitable growth with a CAGR of 6.7% for the period from 2018 to 2026
  • Based on the API type, the synthetic chemical segment shows lucrative growth with increasing applications in the therapeutic treatment procedures.
  • The development of the worldwide active pharmaceutical ingredient is mainly contributed the high demand for innovative therapeutics, a rise in FDA approvals, for new molecules and drugs, and expansion of the manufacturing capacity in the overseas market.
  • In addition, new technology assessment in API manufacturing along with the existence of top API manufacturers & sophisticated healthcare facilities in the developed nations is further going to spur revenue growth during the forecast period.
  • Eastern Europe, Latin America, and the Asia Pacific to show promising opportunities and shows growing CAGR during the forecast period owing to rising manufacturing capacity for active pharmaceutical ingredient and dosage pattern for various treatment. Surging population & along with ease in availability of drugs and medications, and increasing healthcare spending in Russia, Brazil, India, China, and Japan may contribute to the growth of the market during the forecast period.
  • Major players in this vertical are Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi, Boehringer Ingelheim, Novartis International AG, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc. and AbbVie Inc., Lonza Group and others.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Lonza Group
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Active Pharmaceutical Ingredient Market Portraiture
2.2. Global Active Pharmaceutical Ingredient Market, By API Type, 2017 (US$ Mn)
2.3. Global Active Pharmaceutical Ingredient Market, By Drug Type, 2017 (US$ Mn)
2.4. Global Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2017 (US$ Mn)
2.5. Global Active Pharmaceutical Ingredient Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Active Pharmaceutical Ingredient Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Active Pharmaceutical Ingredient Technologies: Future Trends
3.3. Current Scenario: Strategies Used for Shifting Manufacturing Plants Internationally
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Active Pharmaceutical Ingredient Market, by API Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Synthetic Chemical API
4.3. Biological API

Chapter 5. Global Active Pharmaceutical Ingredient Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Branded Drugs
5.3. Generic Drugs
5.4. OTC Drugs

Chapter 6. Global Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2016 – 2026 (US$)
6.1. Overview
6.2. Contract Manufacturers
6.3. Captive Manufacturers

Chapter 7. Global Active Pharmaceutical Ingredient Market, by Geography, 2016 – 2026 (US$ Mn)
7.1. Overview
7.2. North America Active Pharmaceutical Ingredient Market Analysis, 2016 – 2026
7.2.1. North America Active Pharmaceutical Ingredient Market, By API Type, 2016 – 2026 (US$ Mn)
7.2.2. North America Active Pharmaceutical Ingredient Market, By Drug Type, 2016 – 2026 (US$ Mn)
7.2.3. North America Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2016 – 2026 (US$ Mn)
7.2.4. North America Active Pharmaceutical Ingredient Market, by Country, 2016 – 2026 (US$ Mn)
7.2.4.1. U.S.
7.2.4.2. Canada
7.3. Europe Active Pharmaceutical Ingredient Market Analysis, 2016 – 2026
7.3.1. Europe Active Pharmaceutical Ingredient Market, By API Type, 2016 – 2026 (US$ Mn)
7.3.2. Europe Active Pharmaceutical Ingredient Market, By Drug Type, 2016 – 2026 (US$ Mn)
7.3.3. Europe Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2016 – 2026 (US$ Mn)
7.3.4. Europe Active Pharmaceutical Ingredient Market, by Country, 2016 – 2026 (US$ Mn)
7.3.4.1. U.K.
7.3.4.2. Germany
7.3.4.3. Rest of Europe
7.4. Asia Pacific Active Pharmaceutical Ingredient Market Analysis, 2016 – 2026
7.4.1. Asia Pacific Active Pharmaceutical Ingredient Market, By API Type, 2016 – 2026 (US$ Mn)
7.4.2. Asia Pacific Active Pharmaceutical Ingredient Market, By Drug Type, 2016 – 2026 (US$ Mn)
7.4.3. Asia Pacific Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2016 – 2026 (US$ Mn)
7.4.4. Asia Pacific Active Pharmaceutical Ingredient Market, by Country, 2016 – 2026 (US$ Mn)
7.4.4.1. Japan
7.4.4.2. China
7.4.4.3. Rest of APAC
7.5. Latin America Active Pharmaceutical Ingredient Market Analysis, 2016 – 2026
7.5.1. Latin America Active Pharmaceutical Ingredient Market, By API Type, 2016 – 2026 (US$ Mn)
7.5.2. Latin America Active Pharmaceutical Ingredient Market, By Drug Type, 2016 – 2026 (US$ Mn)
7.5.3. Latin America Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2016 – 2026 (US$ Mn)
7.5.4. Latin America Active Pharmaceutical Ingredient Market, by Country, 2016 – 2026 (US$ Mn)
7.5.4.1. Brazil
7.5.4.2. Mexico
7.5.4.3. Rest of Latin America
7.6. Middle East & Africa (MEA) Active Pharmaceutical Ingredient Market Analysis, 2016 – 2026
7.6.1. MEA Active Pharmaceutical Ingredient Market, by API Type, 2016 – 2026 (US$ Mn)
7.6.2. MEA Active Pharmaceutical Ingredient Market, by Drug Type, 2016 – 2026 (US$ Mn)
7.6.3. MEA Active Pharmaceutical Ingredient Market, By Manufacturing Type, 2016 – 2026 (US$ Mn)
7.6.4. MEA Active Pharmaceutical Ingredient Market, by Region, 2016 – 2026 (US$ Mn)
7.6.4.1. GCC
7.6.4.2. Rest of MEA

Chapter 8. Company Profiles
8.1. Teva Pharmaceutical Industries Ltd.
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Pfizer, Inc.
8.3. Sanofi
8.4. Boehringer Ingelheim
8.5. Novartis International AG
8.6. Bristol-Myers Squibb
8.7. Eli Lilly and Company
8.8. GlaxoSmithKline plc
8.9. Merck & Co., Inc.
8.10. AbbVie Inc.
8.11. Lonza Group

List of Figures
FIG. 1 Global Active Pharmaceutical Ingredient Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Active Pharmaceutical Ingredient Market Segmentation
FIG. 4 Global Active Pharmaceutical Ingredient Market, by API Type, 2017 (US$ Mn)
FIG. 5 Global Active Pharmaceutical Ingredient Market, by Drug Type, 2017 (US$ Mn)
FIG. 6 Global Active Pharmaceutical Ingredient Market, by Manufacturing Type, 2017 (US$ Mn)
FIG. 7 Global Active Pharmaceutical Ingredient Market, by Geography, 2017 (US$ Mn)
FIG. 8 Attractive Investment Proposition, by Geography, 2017
FIG. 9 Global Market Positioning of Key Active Pharmaceutical Ingredient Manufacturers, 2017
FIG. 10 Global Synthetic Chemical API Type Market, 2016–2026 (US$ Mn)
FIG. 11 Global Biological API Type Market, 2016–2026 (US$ Mn)
FIG. 12 Global Branded Drugs Market, Active Pharmaceutical Ingredient, 2016–2026 (US$ Mn)
FIG. 13 Global Generic Drugs for Active Pharmaceutical Ingredient, 2016–2026 (US$ Mn)
FIG. 14 Global OTC Drugs Market for Active Pharmaceutical Ingredient, 2016–2026 (US$ Mn)
FIG. 15 Global Contract Manufacturers Market for Active Pharmaceutical Ingredient, 2016–2026 (US$ Mn)
FIG. 16 Global Captive Manufacturers Market for Active Pharmaceutical Ingredient, 2016–2026 (US$ Mn)
FIG. 17 U.S. Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 18 Canada Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 19 U.K. Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 20 Germany Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 21 Rest of Europe Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 22 Japan Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 23 China Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 24 Rest of Asia Pacific Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 25 Brazil Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 26 Mexico Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 27 Rest of Latin America Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 28 GCC Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)
FIG. 29 Rest of Middle East & Africa Active Pharmaceutical Ingredient Market, 2016–2026 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Active Pharmaceutical Ingredient Market
TABLE 2 Global Active Pharmaceutical Ingredient Market, by API Type, 2016–2026 (US$ Mn)
TABLE 3 Global Active Pharmaceutical Ingredient Market, by Drug Type, 2016–2026 (US$ Mn)
TABLE 4 Global Active Pharmaceutical Ingredient Market, by Manufacturing Type, 2016–2026 (US$ Mn)
TABLE 5 Global Active Pharmaceutical Ingredient Market, by Geography, 2016–2026 (US$ Mn)
TABLE 6 North America Active Pharmaceutical Ingredient Market, by API Type, 2016–2026 (US$ Mn)
TABLE 7 North America Active Pharmaceutical Ingredient Market, by Drug Type, 2016–2026 (US$ Mn)
TABLE 8 North America Active Pharmaceutical Ingredient Market, by Manufacturing Type, 2016–2026 (US$ Mn)
TABLE 9 North America Active Pharmaceutical Ingredient Market, by Country, 2016–2026 (US$ Mn)
TABLE 10 Europe Active Pharmaceutical Ingredient Market, by API Type, 2016–2026 (US$ Mn)
TABLE 11 Europe Active Pharmaceutical Ingredient Market, by Drug Type, 2016–2026 (US$ Mn)
TABLE 12 Europe Active Pharmaceutical Ingredient Market, by Manufacturing Type, 2016–2026 (US$ Mn)
TABLE 13 Europe Active Pharmaceutical Ingredient Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 14 Latin America Active Pharmaceutical Ingredient Market, by API Type, 2016–2026 (US$ Mn)
TABLE 15 Latin America Active Pharmaceutical Ingredient Market, by Drug Type, 2016–2026 (US$ Mn)
TABLE 16 Latin America Active Pharmaceutical Ingredient Market, by Manufacturing Type, 2016–2026 (US$ Mn)
TABLE 17 Latin America Active Pharmaceutical Ingredient Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 18 Asia Pacific Active Pharmaceutical Ingredient Market, by API Type, 2016–2026 (US$ Mn)
TABLE 19 Asia Pacific Active Pharmaceutical Ingredient Market, by Drug Type, 2016–2026 (US$ Mn)
TABLE 20 Asia Pacific Active Pharmaceutical Ingredient Market, by Manufacturing Type, 2016–2026 (US$ Mn)
TABLE 21 Asia Pacific Active Pharmaceutical Ingredient Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 22 Middle East & Africa Active Pharmaceutical Ingredient Market, by API Type, 2016–2026 (US$ Mn)
TABLE 23 Middle East & Africa Active Pharmaceutical Ingredient Market, by Drug Type, 2016–2026 (US$ Mn)
TABLE 24 Middle East & Africa Active Pharmaceutical Ingredient Market, by Manufacturing Type, 2016–2026 (US$ Mn)
TABLE 25 Middle East & Africa Active Pharmaceutical Ingredient Market, by Region, 2016–2026 (US$ Mn)
TABLE 26 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 27 Pfizer, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 28 Sanofi: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 29 Boehringer Ingelheim: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 30 Novartis International AG.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 31 Bristol-Myers Squibb: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 32 Eli Lilly and Company: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 33 GlaxoSmithKline plc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 34 Merck & Co., Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 35 AbbVie Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 36 Lonza Group: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Sanofi
  • Boehringer Ingelheim
  • Novartis International AG
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Lonza Group
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4701683
Adroll
adroll